Loading...
01/10 00:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
Revenue for Q3 2025 $5.4 million, up 23% year-over-year compared to $4.4 million for the same period in 2024. The increase was primarily driven by higher development services revenue, including additional contracts with DoD.
Gross Profit for Q3 2025 $0.9 million or 16.5% of revenue, compared to $0.7 million or 15.5% in the prior year period. The increase was due to a more favorable revenue mix.
R&D Expenses for Q3 2025 $3.5 million versus $2.5 million in Q3 2024, reflecting increased investment in the EscharEx VALUE Phase III study and related clinical activities.
SG&A Expenses for Q3 2025 $4 million compared to $3.2 million in the same period last year. The increase was primarily due to marketing authorization holder expenses.
Operating Loss for Q3 2025 $6.5 million compared to $5.1 million in Q3 2024. The increase was due to higher R&D and SG&A expenses.
Net Loss for Q3 2025 $2.7 million or $0.24 per share compared to a net loss of $10.3 million or $0.98 per share in Q3 2024. The improvement was mainly driven by noncash financial income from the revaluation of warrants this quarter compared to noncash financial expenses from warrant revaluation in Q3 2024.
Adjusted EBITDA Loss for Q3 2025 $5.4 million compared to a loss of $3.7 million in Q3 2024.
Revenue for First 9 Months of 2025 $15.1 million compared to $14.4 million in the same period of 2024. The increase was driven by higher development services revenue.
Gross Profit for First 9 Months of 2025 $3 million or 19.7% of revenue compared to $1.7 million or 12% in the first 9 months of 2024. The margin improvement was driven by a more favorable revenue mix.
R&D Expenses for First 9 Months of 2025 $9.8 million compared to $5.9 million in the same period of 2024, reflecting increased investment in clinical activities.
SG&A Expenses for First 9 Months of 2025 $10.6 million versus $9.1 million in the first 9 months of 2024. The increase was primarily due to marketing authorization holder expenses.
Operating Loss for First 9 Months of 2025 $17.5 million compared to $13.3 million in the same period of 2024.
Net Loss for First 9 Months of 2025 $16.7 million or $1.53 per share compared to $26.3 million or $2.72 per share in the same period of 2024. The reduction in net loss was primarily driven by noncash financial income from the revaluation of warrants in 2025 compared to noncash financial expenses from revaluation of warrants in 2024.
Adjusted EBITDA Loss for First 9 Months of 2025 $13.9 million compared to $9.9 million in the prior year period.
Cash Position as of September 30, 2025 $60 million in cash, cash equivalents and short-term deposits compared to $44 million at year-end 2024. The increase was due to a $30 million registered direct offering and $3.5 million in proceeds from Series A warrant exercises.
EscharEx VALUE Phase III trial: Enrollment is progressing with a target of 216 patients across 40 sites in the US and Europe. Interim sample size assessment will occur after 65% of patients complete treatment. The trial focuses on complete debridement and wound closure, with potential annual peak sales estimated at $831 million.
Diabetic Foot Ulcer (DFU) program: Received positive FDA feedback and awaiting EMA advice. Study initiation planned for the second half of 2026.
NexoBrid: Expanded manufacturing facility completed, increasing production capacity 6x. Full operational capacity expected by year-end 2025. Record quarterly revenue in the US, up 38% year-over-year.
EscharEx market positioning: Medicare reduced reimbursement rates for skin substitute products, increasing EscharEx's attractiveness. A single legacy product in the enzymatic debridement segment generates $370 million annually.
NexoBrid global expansion: Approved in Australia for adult and pediatric patients, bringing total approved markets to 45 countries. Featured in 36 scientific presentations at the European Burn Association Congress.
NexoBrid manufacturing expansion: Expanded facility increases production capacity 6x, ensuring reliable supply and meeting global demand.
Financial position: Strengthened with $30 million equity financing, providing resources for long-term growth strategy.
BARDA collaboration: Multiyear program for stockpiling and development of new formulations paused due to government shutdown but expected to resume.
Corporate financial strategy: Improved cash position with $60 million in reserves, supporting strategic priorities and operational activities.
EscharEx VLU trial: Several EU sites required additional adjustments to meet ancillary-related regulatory requirements, creating potential uncertainty in the overall study timeline.
NexoBrid manufacturing expansion: The expansion process faced challenges such as a 2-year war, personnel drafting, and import delays on specialized equipment, which could have impacted timelines and operational efficiency.
BARDA collaboration: The U.S. government shutdown caused a pause in BARDA-related activities, creating uncertainty around the timing of BARDA and DOD-related revenue in Q4.
Financial performance: Operating loss increased to $6.5 million in Q3 2025 compared to $5.1 million in Q3 2024, and adjusted EBITDA loss also widened, reflecting higher R&D and SG&A expenses.
EscharEx VALUE Phase III trial: Enrollment is progressing with a target of 216 patients across 40 sites in the US and Europe. Interim sample size assessment will occur after 65% of patients complete treatment. The company plans to initiate a diabetic foot ulcer study in the second half of 2026.
NexoBrid manufacturing expansion: The expanded manufacturing facility is expected to reach full operational capacity by year-end 2025, with regulatory review determining the timing of commercial output.
BARDA collaboration: Activities related to stockpiling and development of new formulations are expected to resume following the end of the government shutdown.
EscharEx market potential: Updated U.S. market access and pricing assessment estimates annual peak sales of $831 million, supported by robust clinical data and health economic benefits.
NexoBrid commercial growth: Production capacity has increased sixfold, and the product has been approved in 45 countries. U.S. partner Vericel plans to pursue a permanent CPT code by 2027.
Financial outlook: The company has $60 million in cash and expects this to provide financial flexibility to advance key programs and execute strategic priorities.
The selected topic was not discussed during the call.
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
The earnings call presented mixed signals. While strategic collaborations and funding are positive, the decline in revenue and increased operating loss are concerning. The Q&A highlighted ongoing projects and potential future benefits but also revealed some uncertainties, particularly regarding patient recruitment and manufacturing timelines. Despite some positive developments, the overall financial health and lack of immediate catalysts suggest a neutral market reaction.
The earnings call reveals several challenges: declining revenue, increased operating loss, and competitive pressures against EscharEx. Despite some positive developments, such as the new manufacturing facility and improved gross margin, these are overshadowed by financial struggles and supply chain issues. The Q&A session highlighted regulatory uncertainties and management's vague responses about future government purchases and financial projections. Without a share repurchase program or positive shareholder return plan, the overall sentiment is negative, likely leading to a stock price decline of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
